INX-08189, a Phosphoramidate Prodrug of 6-O-Methyl-2′-C-Methyl Guanosine, Is a Potent Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic and Pharmacodynamic Properties

PSI-7851, a Pronucleotide of  -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication

(2010) A. M. Lam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus

(2010) Christopher McGuigan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

2013 ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED SUBJECTS

(2010) J. Lalezari et al.   JOURNAL OF HEPATOLOGY

Phosphoramidate ProTides of 2′-C-Methylguanosine as Highly Potent Inhibitors of Hepatitis C Virus. Study of Their in Vitro and in Vivo Properties

(2010) Christopher McGuigan et al.   JOURNAL OF MEDICINAL CHEMISTRY

The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4′-azidocytidine (R1479)

(2009) Christopher McGuigan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The phosphoramidate ProTide approach greatly enhances the activity of β-2′-C-methylguanosine against hepatitis C virus

(2009) Christopher McGuigan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women

(2009) P. D. Dryer et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

958 NO EVIDENCE OF R7128 DRUG RESISTANCE AFTER UP TO 4 WEEKS TREATMENT OF GT 1, 2 AND 3 HEPATITIS C VIRUS INFECTED INDIVIDUALS

(2009) S. Le Pogam et al.   JOURNAL OF HEPATOLOGY

Phosphoramidate Prodrugs of 2′-C-Methylcytidine for Therapy of Hepatitis C Virus Infection

(2009) Cristina Gardelli et al.   JOURNAL OF MEDICINAL CHEMISTRY

HCV drug discovery aimed at viral eradication

(2009) R. F. Schinazi et al.   JOURNAL OF VIRAL HEPATITIS

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

(2008) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY